Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Zoetis Inc. director Louise M. Parent reported equity award activity involving restricted stock units (RSUs). On February 19, 2026, RSUs were exercised into 1,619 shares of common stock, increasing her direct common stock holdings to 16,879 shares. The filing also records a disposition of 615 shares back to Zoetis Inc. for cash based on the closing share price of $127.28, leaving 16,264 common shares directly held. Following these transactions, she also directly holds 1,936 RSUs, each representing a contingent right to receive one Zoetis common share, with future RSUs scheduled to vest and settle in shares on the first anniversary of their grant dates.
Zoetis Inc. director Willie M. Reed acquired company stock through restricted stock unit (RSU) vesting. On February 19, 2026, 1,619.3325 RSUs were exercised at $0.0000 per share, resulting in 1,619 shares of Zoetis common stock being issued.
Following the transaction, Reed directly owned 12,864 Zoetis common shares and held 1,936 RSUs, each representing a right to receive one share. The remaining RSUs are scheduled to vest and be settled in Zoetis common stock on February 18, 2026, subject to continued service and certain earlier-vesting events.
Zoetis Inc. director Sanjay Khosla reported an equity award in the form of restricted stock units. He acquired 1,936 RSUs on February 18, 2026 under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan. Each RSU represents a contingent right to receive one share of Zoetis common stock.
The footnotes state these RSUs will vest and be settled in Zoetis common shares on the first anniversary of the grant date, February 18, 2026, subject to his continued service and certain earlier-vesting events. The filing also updates holdings from a prior RSU grant scheduled to vest on February 19, 2025.
Esch Kevin reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Kevin Esch received new equity awards on February 18, 2026. He was granted 4,026 restricted stock units and 15,931 stock options at a price of $0 per unit or option. Each RSU represents a contingent right to one Zoetis common share.
One-third of each RSU and one-third of each option will vest on the first, second, and third anniversaries of the grant date, February 18, 2026, subject to his continued service and possible earlier vesting upon certain specified events. Each option expires on the tenth anniversary of the grant date.
Bisaro Paul reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Paul Bisaro reported an equity compensation award in the form of 1,936 restricted stock units on February 18, 2026. These RSUs were granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan and represent a contingent right to receive an equal number of Zoetis common shares.
Each RSU will vest and be settled in Zoetis common stock on the first anniversary of the grant date, February 18, 2026, subject to his continued service and certain earlier‑vesting events. A separate line reflects his existing RSU holdings, which totaled 1,619.3325 units after earlier grants and related dividend equivalents.
Zoetis Inc. reported that Executive Vice President Ferran Astorga Jeannette received new equity awards. On February 18, 2026, the executive was granted 2,197 restricted stock units and 8,693 stock options at an exercise price of $0.00 per option.
Each restricted stock unit represents a contingent right to receive one share of Zoetis common stock. One-third of both the RSUs and stock options will vest on the first, second, and third anniversaries of the February 18, 2026 grant date, subject to continued service and earlier vesting upon certain specific events.
Tilenius Stephanie reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Stephanie Tilenius reported an equity award of 1,936 restricted stock units (RSUs). The RSUs were granted at no cash cost under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
Each RSU represents a contingent right to receive one share of Zoetis common stock. These RSUs are scheduled to vest and settle in shares on the first anniversary of the grant date, February 18, 2026, assuming continued service and subject to earlier vesting upon certain specified events. Following the reported transactions, Tilenius directly holds 1,972.4463 RSUs, including units from a prior grant dated December 1, 2025 that vest on its first anniversary.
Sarbaugh Keith reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Keith Sarbaugh reported new equity awards. On February 18, 2026, he received 2,674 restricted stock units and 10,581 stock options under the Zoetis Amended and Restated 2013 Equity and Incentive Plan.
The RSUs each represent one share of common stock and vest in three equal installments on the first, second and third anniversaries of the grant date, subject to continued service and certain earlier-vesting events. The stock options also vest one‑third per year over three years from the grant date and expire on the tenth anniversary.
DAMELIO FRANK A reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Frank A. D'Amelio reported an equity compensation award of 1,936 restricted stock units (RSUs) granted on February 18, 2026 under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan. The award was recorded at a price of $0.00 per unit, reflecting that this is a grant, not a market purchase.
Each RSU represents a contingent right to receive one share of Zoetis common stock. According to the terms described, each RSU will vest and be settled in Zoetis common shares on the first anniversary of the date of grant, February 18, 2026, subject to D'Amelio's continued service and certain earlier-vesting events.
FULLER JULIE reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Julie Fuller reported new equity awards in the latest Form 4. On February 18, 2026, she was granted 3,626 restricted stock units and 14,345 stock options under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
Each RSU represents a right to receive one share of Zoetis common stock, with one-third of the RSUs scheduled to vest on each of the first, second and third anniversaries of the February 18, 2026 grant date, subject to continued service and certain earlier-vesting events. The stock options vest on the same one-third annual schedule and each option expires on the tenth anniversary of the grant date.